Aditx Therapeutics, Inc. (ADTX)
Stock Price:
$1.83 USD
0.12 (7.02%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
After-hours: $1.85 +0.02 (1.09%) Sep 25, 7:31 PM
Key Info
| Market Cap |
17.35M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
9.48M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 25, 2020 |
| Last Price |
$1.83 |
| Previous Close |
$1.71 |
| Change ($) |
0.12 |
| Change (%) |
7.02% |
| Day's Open |
1.66 |
| Day's Range |
1.66 - 1.85 |
| Day's Volume |
503,088 |
| 52-Week Range |
1.62 - 9.58 |
More Stats
| Market Cap |
17.35M |
| Enterprise Value |
18.14M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
9.48M |
| Float |
5.54M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
180,678 |
| Short Ratio |
0.02 |
| Short % of Float |
1.29% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
-790,675 |
| Net Cash / Share |
-0.08 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -5.87 | -5.61 |
| Net Income | -5.83 | -5.69 |
| Shares Outstanding | 3.83 | 3.63 |
| Earnings Per Share | -1.52 | -1.57 |
| Operating Cash Flow | -0.46 | -0.39 |
| Free Cash Flow | -0.46 | -0.39 |
| Cash & Equivalents | 0.00 | 0.12 |
| Total Debt | 0.17 | 0.16 |
| Net Cash / Debt | -0.16 | -0.05 |
| Assets | 0.12 | 0.12 |
| Liabilities | 2.98 | 1.65 |
| Book Value | -2.85 | -1.54 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aditx Therapeutics, Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Amro Albanna |
Stock Information
| Ticker Symbol |
ADTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ADTX |
| IPO Date |
June 30, 2020 |
Description
ADiTx Therapeutics, a life sciences company, focuses on developing nucleic acid-based technologies for addressing the rejection of transplanted organs, autoimmune diseases, and allergies. The company is developing Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that utilizes an approach, which mimics the way the body naturally induces tolerance to its own tissues. It also develops ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was founded in 2017 and is headquartered in Loma Linda, California.